Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017090743) NOVEL IMIDAZOLE COMPOUND AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONIST
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/090743 International Application No.: PCT/JP2016/085017
Publication Date: 01.06.2017 International Filing Date: 25.11.2016
IPC:
C07D 401/14 (2006.01) ,A61K 31/454 (2006.01) ,A61K 31/4725 (2006.01) ,A61K 31/5377 (2006.01) ,A61K 31/541 (2006.01) ,A61P 29/00 (2006.01) ,A61P 37/02 (2006.01) ,C07D 403/12 (2006.01) ,C07D 403/14 (2006.01) ,C07D 413/14 (2006.01) ,C07D 417/14 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4523
containing further heterocyclic ring systems
454
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
472
Non-condensed isoquinolines, e.g. papaverine
4725
containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375
1,4-Oxazines, e.g. morpholine
5377
not condensed and containing further heterocyclic rings, e.g. timolol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
54
having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
541
Non-condensed thiazines containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
02
Immunomodulators
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14
containing three or more hetero rings
Applicants:
田辺三菱製薬株式会社 MITSUBISHI TANABE PHARMA CORPORATION [JP/JP]; 大阪府大阪市中央区道修町三丁目2番10号 3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 5418505, JP
Inventors:
佐藤 篤史 SATO, Atsushi; JP
今城 律雄 IMASHIRO, Ritsuo; JP
辻嶋 秀一 TSUJISHIMA, Hidekazu; JP
谷本 晃一 TANIMOTO, Kouichi; JP
山元 康王 YAMAMOTO, Yasuo; JP
中根 哲 NAKANE, Tetsu; JP
利川 千尋 TOSHIKAWA, Chihiro; JP
Agent:
鮫島 睦 SAMEJIMA, Mutsumi; JP
森本 靖 MORIMOTO, Yasushi; JP
秋山 信彦 AKIYAMA, Nobuhiko; JP
Priority Data:
2015-23174527.11.2015JP
Title (EN) NOVEL IMIDAZOLE COMPOUND AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONIST
(FR) NOUVEAU COMPOSÉ D’IMIDAZOLE ET SON UTILISATION EN TANT QU'AGONISTE DU RÉCEPTEUR DE LA MÉLANOCORTINE
(JA) 新規イミダゾール化合物およびメラノコルチン受容体作動薬としての用途
Abstract:
(EN) The present invention pertains to a novel imidazole compound having melanocortin receptor agonist activity, or a pharmacologically acceptable salt thereof, and medicinal use thereof. The present invention pertains to an imidazole compound represented by general formula (I) (in the formula, ring A represents an optionally substituted aryl group or the like; R1 represents a hydrogen atom, an optionally substituted alkyl group, or the like; R2 represents a hydrogen atom, a halogen atom, or the like; and R3 represents an optionally substituted alkyl group), or a pharmacologically acceptable salt thereof.
(FR) La présente invention concerne un nouveau composé d'imidazole présentant une activité agoniste du récepteur de la mélanocortine, ou son sel pharmacologiquement acceptable, et son utilisation médicale. La présente invention concerne un composé d’imidazole représenté par la formule générale (I) (dans la formule, le cycle A représente un groupe aryle facultativement substitué ou similaire ; R1 représente un atome d'hydrogène, un groupe alkyle éventuellement substitué ou similaire ; R2 représente un atome d'hydrogène, un atome d'halogène, ou similaire ; et R3 représente un groupe alkyle éventuellement substitué), ou son sel pharmacologiquement acceptable.
(JA) 本発明は、メラノコルチン受容体作動活性を有する新規イミダゾール化合物又はその薬理的に許容し得る塩及びその医薬用途に関する。本発明は、一般式〔I〕 〔式中、環Aは置換されていてもよいアリール基等を表し;Rは水素原子、置換されていてもよいアルキル基等を表し;Rは水素原子、ハロゲン原子等を表し;Rは置換されていてもよいアルキル基を表す〕で示されるイミダゾール化合物、又はその薬理的に許容し得る塩に関する。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)
Also published as:
US20180258076EP3381913